

NDA 013217/S-062

## **SUPPLEMENT APPROVAL**

King Pharmaceuticals R&D LLC  
c/o Pfizer Inc.  
66 Hudson Boulevard East  
New York, NY 10001

Attention: Lisa Amatulli  
Senior Manager, Pfizer Global Regulatory Sciences

Dear Lisa Amatulli:

Please refer to your supplemental new drug application (sNDA) dated and received December 21, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Skelaxin (metaxalone) tablets, 800 mg.

This Prior Approval sNDA provides for conversion of the Prescribing Information into Physician Labeling Rule (PLR) format. Additionally labeling updates were made to be consistent with labeling regulations (e.g., required pediatric and geriatric use regulatory statements) to reduce the risk of medication errors, and to update the signs, symptoms, and complications associated with a metaxalone overdose as well as the recommendations for treatment of overdose. Updates were made to the DOSAGE AND ADMINISTRATION, USE IN SPECIFIC POPULATIONS, OVERDOSAGE, and CLINICAL PHARMACOLOGY sections of labeling.

### **APPROVAL & LABELING**

We have completed our review of this sNDA, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (Prescribing Information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, email Hyejin Lai, PharmD, Regulatory Project Manager, at [Hyejin.lai@fda.hhs.gov](mailto:Hyejin.lai@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Rigoberto Roca, MD  
Director  
Division of Anesthesiology, Addiction Medicine,  
and Pain Medicine  
Office of Neuroscience  
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

RIGOBERTO A ROCA  
06/21/2024 10:15:59 AM